AN OBSERVATIONAL STUDY ON CLINICAL SAFETY AND EFFICACY OF TELMISARTAN IN PATIENTS WITH CORONARY ARTERY DISEASE

Background: The most prevalent kind of cardiac illness is coronary artery disease, it develops when the blood vessels are blocked due to the accumulation of cholesterol, and fatty deposits(plaques) which leads to a decline in the supply of blood to the heart and may cause chest pain (angina), SOB which results in cardiac problems like CAD/IHD, MI, or heart failure. Telmisartan is a angiotensin 2 receptor blocker. It works by blocking an internal substance that causes the tightening of blood vessels and alters their relationship, further resulting in reduced blood pressure and supplying the heart with more blood and oxygen. Methods: A total of 70 case records of patients were included in an observational study on the clinical safety and efficacy of telmisartan in patients with CAD that was conducted for six months. In this study, patients were considered by age, gender, BMI, co-morbidities, and different doses of a drug. This analysis was conducted through a patient-level survey conducted in both OP and IP hospital departments, aiming to discern the safety and efficacy of telmisartan. Results: Within the study, telmisartan was prescribed to individuals aged 35-85 years for both male and female patients. The prescribed doses were in doses i.e. 20mg, 40mg, and 80mg. In a sample of 70 patients, the efficacy of telmisartan is 100% i.e. using telmisartan in CAD patients reduces the blood pressure and reduces the workload of the heart. This indicates a substantial and positive effect on high blood pressure. Conclusion: In this observational study, telmisartan was prescribed to lower the blood pressure in CAD patients. No patients experienced serious adverse effects associated with the use of telmisartan. However, 10% of participants have experienced minor side effects such as dizziness, itching, and nausea.